Liquid biopsy results differed substantially between two providers in a study

FDA grants de novo authorization for PGDx elio plasma focus Dx, a kitted, pan-solid tumor liquid biopsy test

Labcorp announced it has received de novo marketing authorization from FDA for PGDx elio plasma focus Dx—the industry’s first and only kitted, pan-solid tumor liquid biopsy test.

August 09, 2024

Vol.50 No.32

Clinical Roundup

Novel liquid biopsy methodology can track evolution of metastatic prostate cancer

DNA/RNA material contained in circulating extracellular vesicles secreted into the bloodstream by tumor cells captures cancer genomics and transcriptomic evolution in patients with metastatic prostate cancer, according to a new study.

July 26, 2024

Vol.50 No.30

Clinical Roundup

AI-based blood test outperforms ultrasound in early liver cancer detection

Helio Genomics, an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, has released results from its latest clinical trial demonstrating the superior performance of their HelioLiver Dx test compared to ultrasound.

June 14, 2024

Vol.50 No.24

Drugs & Targets

FDA advisory committee recommends approval of Shield blood test for colorectal cancer screening

FDA’s Medical Devices Advisory Committee has strongly recommended FDA approval of Guardant Health’s Shield blood test for colorectal cancer screening in adults age 45 and older who are at average risk for the disease.

May 24, 2024

Vol.50 No.21

Clinical Roundup

Epigenomic platform may predict NSCLC immunotherapy response using liquid biopsies

Data published in The Journal for ImmunoTherapy of Cancer show ClearNote Health’s epigenomic platform may provide a novel tissue-free, liquid biopsy-based approach for prediction and monitoring of immunotherapy response for non-small cell lung cancer patients.

January 19, 2024

Vol.50 No.03

Regulatory News

Heated discussion breaks out in recent meeting as FDA mulls standards for MCD approval
Meanwhile, NCI trial will assess clinical utility

Multi-cancer detection tests evoke conflicting reactions—the excitement at their promise is quickly dampened by concerns over the uncertainty of their clinical benefit, very low sensitivity for detecting stage 1 cancers, and the risks that come from subsequent workups.

January 12, 2024

Vol.50 No.02

By Jacquelyn Cobb

Liquid biopsy results differed substantially between two providers in a study

YOU MAY BE INTERESTED IN

FDA grants de novo authorization for PGDx elio plasma focus Dx, a kitted, pan-solid tumor liquid biopsy test

Novel liquid biopsy methodology can track evolution of metastatic prostate cancer

AI-based blood test outperforms ultrasound in early liver cancer detection

FDA advisory committee recommends approval of Shield blood test for colorectal cancer screening

Epigenomic platform may predict NSCLC immunotherapy response using liquid biopsies

Heated discussion breaks out in recent meeting as FDA mulls standards for MCD approval
Meanwhile, NCI trial will assess clinical utility

Renew today!

Subscriber content

Never miss an issue!

Login

Liquid biopsy results differed substantially between two providers in a study

YOU MAY BE INTERESTED IN

FDA grants de novo authorization for PGDx elio plasma focus Dx, a kitted, pan-solid tumor liquid biopsy test

Novel liquid biopsy methodology can track evolution of metastatic prostate cancer

AI-based blood test outperforms ultrasound in early liver cancer detection

FDA advisory committee recommends approval of Shield blood test for colorectal cancer screening

Epigenomic platform may predict NSCLC immunotherapy response using liquid biopsies

Heated discussion breaks out in recent meeting as FDA mulls standards for MCD approvalMeanwhile, NCI trial will assess clinical utility

Never miss an issue!

Login

Heated discussion breaks out in recent meeting as FDA mulls standards for MCD approval
Meanwhile, NCI trial will assess clinical utility